ADAM17 is understood to be involved in the processing of tumor necrosis factor alpha (
TNF-α) at the surface of the
cell, and from within the
intracellular membranes of the
trans-Golgi network. This process, which is also known as 'shedding', involves the cleavage and release of a soluble ectodomain from membrane-bound pro-proteins (such as pro-TNF-α), and is of known physiological importance. ADAM17 was the first '
sheddase' to be identified, and is also understood to play a role in the release of a diverse variety of membrane-anchored
cytokines,
cell adhesion molecules,
receptors,
ligands, and enzymes. Cloning of the TNF-α
gene revealed it to encode a 26 kDa type II transmembrane pro-polypeptide that becomes inserted into the cell membrane during its maturation. At the cell surface, pro-TNF-α is biologically active, and is able to induce immune responses via
juxtacrine intercellular signaling. However, pro-TNF-α can undergo a
proteolytic cleavage at its Ala76-Val77 amide bond, which releases a soluble 17kDa extracellular domain (
ectodomain) from the pro-TNF-α molecule. This soluble ectodomain is the cytokine commonly known as TNF-α, which is of pivotal importance in paracrine signaling. This proteolytic liberation of soluble TNF-α is catalyzed by ADAM17. ADAM17 may play a prominent role in the
Notch signaling pathway, during the proteolytic release of the Notch intracellular domain (from the Notch1 receptor) that occurs following ligand binding. ADAM17 also regulates the MAP kinase signaling pathway by regulating shedding of the EGFR ligand amphiregulin in the mammary gland. ADAM17 also has a role in the shedding of
L-selectin, a
cellular adhesion molecule. == Activation ==